How long acting injectables can help improve medication adherence.
A detailed guide of how clozapine works for treatment. Part 2 of 4.
These questions about the patient's history and details on antipsychotic class and depot delivery technology will help in making decisions on the appropriate agent to use.
Use the REAP MODEL to guide patients to considering clozapine when there has been a persistence of specific schizophrenia symptoms despite treatment with other antipsychotics. REAP is a shared model for you and your patients to make decisions together, within the evidence base.
This case study follows David, now in his early 20s, who entered treatment at a first episode outpatient clinic following a first inpatient psychiatric admission.
Frequently asked questions covering whether to use clozapine, dosage suggestions, the most common side effects and more.
Long-acting injectable antipsychotic medications (LAIs) are a valuable approach to enhancing medication adherence in patients with schizophrenia. This desk guide is designed to help providers obtain LAI coverage for their patients.
Northwell Health worked alongside research and design company Clinvue to conduct an ethnographic study that interviewed patients, clinicians, providers and payers to understand their perceptions and barriers to use of LAIs. Recording: https://register.gotowebinar.com/recording/4938775727499305730
Learn how to access and navigate the clozapine and long-acting injectable antipsychotics (LAIs) toolkits through the Center for Practice Innovations learning management system. View recording: https://register.gotowebinar.com/recording/5088996501014479874
Join Dr. John Kane and his colleagues from Northwell Health in exploring how to use data to identify optimal candidates for the use of long acting injectable medication and clozapine. https://attendee.gotowebinar.com/recording/2780147417030205185